A randomized, controlled study to evaluate LNP023 (iptacopan) in patients with active ANCA-associated vasculitis.

You likely can't join if

• Other systemic disease which constitutes the primary illness, including but not limited to: eosinophilic granulomatosis with polyangiitis (EGPA), moderate to severe systemic lupus erythematosus, IgA vasculitis (Purpura Schönlein-Henoch), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane (GBM) disease, cryoglobulinemic vasculitis, autoimmune hemolytic anemia, autoimmune lymphoproliferative syndrome or mixed connective tissue disease.
• Alveolar hemorrhage requiring invasive pulmonary ventilation support at Screening.
• Severe kidney disease defined as estimated glomerular filtration rate <15 mL/min/1.73m2, or kidney failure defined as receiving renal replacement therapy such as hemo(dia)filtration, hemo-/peritoneal dialysis, or having received a kidney transplant.
• Received plasma exchange/-pheresis within 12 weeks prior to Screening.
• Received any of the following immunosuppressive, cell depleting or biological therapy (any other immunosuppressive, cell depleting, or biological therapy not listed here must be discussed with the Sponsor): • Received RTX or other B-cell depleting agent within 16 weeks prior to Screening. • Received any of the following biological or alkylating immunosuppressive medications within 12 weeks before screening, including but not limited to: • cyclophosphamide (CYC) • complement inhibitor (such as eculizumab, ravulizumab, avacopan) • anti-tumor necrosis factor • abatacept • tocilizumab • intravenous immunoglobulins • Received any of the following cell depleting agents within 24 weeks before Screening, including but not limited to: • alemtuzumab • antithymocyte globulin • Received azathioprine (AZA), methotrexate (MTX), or mycophenolate (MMF), or any other immunosuppressants with similar half-life within 1 week prior to Day 1. • Received leflunomide (LEF) within 6 weeks prior to Day 1.